Metabolic dysfunction-associated steatotic liver disease, a prevalent health concern closely linked to obesity, affects as many as one million Finns. Yet, its underlying mechanisms remain poorly understood, and treatment options are limited. We investigate how adipose tissue dysfunction—particularly mitochondrial impairment and inflammation—drives this disease. We also explore novel strategies to restore adipose tissue function and improve liver health. We study three cohorts of participants: 1. Identical twin pairs with different body weights 2. Patients undergoing bariatric surgery 3. Patients treated with either the gut hormone-mimicking drug semaglutide or a placebo. We analyze adipose tissue biopsies, asses their mitochondrial metabolism and inflammation, measure liver fat, and monitor gut hormones post-meal. We also explore adipocyte-liver cross-talk in cell models. Our research aims to advance innovative treatments to improve liver health and patient outcomes.

2025

2029